BIOMAT Database Logo BIOMAT Database Logo

A mucormycosis case treated with a combination of caspofungin and amphotericin B. 2013

E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
Uludag University Faculty of Medicine, Infectious Diseases and Clinical Microbiology Department, Görükle, Bursa, Turkey.

Mucormycosis is a rare, invasive and fatal disease that occurs mainly in diabetes mellitus patients with uncontrolled blood glucose levels or in immunocompromised patients. The mortality rate of this disease is as high as 25 to 80%, despite aggressive surgical treatment and antifungal therapy. This high mortality requires alternative treatment approaches. The accepted treatment modality of invasive mucormycosis are amphotericin B lipid formulations. Although echinocandins generally show no activity against Mucorales, it was shown that Rhizopus oryzae expressed the target enzyme for echinocandins, 1,3-beta-glucan synthase. Additionally, there are some experimental studies in a diabetic mouse model and case reports regarding the effects of caspofungin. In this report, we present a rhinocerebral mucormycosis case treated with liposomal amphotericin B and caspofungin. There was regression of the patient's clinical and radiological condition with the addition of caspofungin, but she died due to discontinuation of her treatment and reasons other than mucormycosis.

UI MeSH Term Description Entries
D009091 Mucormycosis Infection in humans and animals caused by any fungus in the order MUCORALES (e.g., RHIZOPUS; MUCOR; CUNNINGHAMELLA; APOPHYSOMYCES; ABSIDIA; SAKSENAEA and RHIZOMUCOR) There are many clinical types associated with infection including central nervous system, lung, gastrointestinal tract, skin, orbit and paranasal sinuses. In humans, it usually occurs as an OPPORTUNISTIC INFECTION. Mucorales Infection,Mucorales Infections,Mucormycoses,Infection, Mucorales,Mucormycose
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077336 Caspofungin A cyclic lipopeptide echinocandin and beta-(1,3)-D-glucan synthase inhibitor that is used to treat internal or systemic MYCOSES. Cancidas,Caspofungin Acetate,Caspofungin MSD,L 743,872,L 743872,L-743,872,L-743872,MK 0991,MK-0991,L743,872,L743872,MK0991
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics
D016867 Immunocompromised Host A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation. Immunosuppressed Host,Immunocompromised Patient,Host, Immunocompromised,Host, Immunosuppressed,Hosts, Immunocompromised,Hosts, Immunosuppressed,Immunocompromised Hosts,Immunocompromised Patients,Immunosuppressed Hosts,Patient, Immunocompromised,Patients, Immunocompromised
D048909 Diabetes Complications Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE. Complications of Diabetes Mellitus,Diabetes-Related Complications,Diabetic Complications,Diabetes Complication,Diabetes Mellitus Complication,Diabetes Mellitus Complications,Diabetes Related Complications,Diabetes-Related Complication,Diabetic Complication

Related Publications

E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
Lessons from a case of oromandibular mucormycosis treated with surgery and a combination of amphotericin B lipid formulation plus caspofungin.
January 2010, Acta haematologica,
E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
Combination of amphotericin B and caspofungin in the treatment of mucormycosis.
December 2019, Medical mycology case reports,
E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
Possible hepatosplenic candidiasis treated with liposomal amphotericin B and caspofungin combination.
May 2006, The Journal of infection,
E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B.
August 2002, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
Combination therapy with caspofungin and amphotericin B lipid complex.
January 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
Caspofungin in combination with amphotericin B against Candida glabrata.
June 2005, Antimicrobial agents and chemotherapy,
E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
Caspofungin in combination with amphotericin B against Candida parapsilosis.
March 2007, Antimicrobial agents and chemotherapy,
E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
Mucormycosis in a Severe Trauma Patient Treated with a Combination of Systemic Posaconazole and Topical Amphotericin B-Case Report.
September 2023, Antibiotics (Basel, Switzerland),
E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis.
August 2006, The Journal of infection,
E Kazak, and E Aslan, and H Akalın, and O Saraydaroğlu, and B Hakyemez, and L Erişen, and B Yazıcı, and E Gürcüoğlu, and E Yılmaz, and B Ener, and S Helvacı
A case of chronic progressive rhinocerebral mucormycosis treated with liposomal amphotericin B and surgery.
April 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!